05:17 AM EDT, 07/15/2026 (MT Newswires) -- EQL Pharma (EQL.ST) said Wednesday that its regional partner Abdi Ibrahim secured marketing approval in Kazakhstan for the 3-milligram strength of its Mellozzan tablets. The Swedish pharmaceutical company expects the 5-mg strength to be approved in December 2026, with the commercial launch of both doses expected in fiscal 2028. Mellozzan contains the sleep hormone melatonin and is indicated for children with attention-deficit/hyperactivity disorder who experience sleep difficulties.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.